In a nutshell This study aimed to compare two salvage chemotherapy regimens for relapsed/refractory acute myeloid leukemia. This study concluded that there were no significant differences between the two regimens apart from cost. Some background Salvage chemotherapy is used to treat cancers that do not respond to other treatments. Relapsed...
Read More
In a nutshell This study investigated the long-term outcomes of MCL (mantle cell lymphoma) patients who received RIST (reduced-intensity allogenic stem cell transplant) therapy. The authors concluded that RIST may be curative in MCL patients, even in those who relapsed after autoSCT (autologous stem cell transplant). Some background Mantle cell...
Read More
In a nutshell This study analyzed the outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who are positive for Epstein-Barr virus (EBV+) or are immunosuppressed (weakened immune system caused by anticancer treatment). The study concluded that these conditions do not impact lymphoma outcomes. Some background Rates of EBV+ DLBCL (diffuse...
Read More
Video information: Inhibitors and targeted therapies have changed the landscape of CLL treatment, so what can patients expect from modern medicine? Dr. Jeff Sharman, from the US Oncology Network, joins our panel to explain the difference in design between newer therapies and chemotherapy. He also shares what newer medicines, like ibrutinib...
Read MoreIn a nutshell This study aimed to evaluate the effectiveness of levofloxacin (Levaquin) in preventing fever due to low white blood cells due to chemotherapy. This study concluded that oral levofloxacin reduced rates of febrile neutropenia. Some background Acute myeloid leukemia patients (AML) can experience complications...
Read More
In a nutshell This study examined the effect of gender on treatment outcomes with chemo-immunotherapy for chronic lymphocytic leukemia (CLL). Researchers reported better survival and disease progression outcomes for female patients receiving rituximab-based (Rituxan) therapy. Some background Men are more likely to develop CLL than women....
Read More
In a nutshell This study investigated the effect of chemotherapy after surgery (CAS) in patients with locally advanced rectal cancer. Researchers suggested that the use of this therapy increases survival of the patients. Some background Surgery is the standard treatment for locally advanced rectal cancer patients. However, the use of CAS...
Read More
In a nutshell This study examined lenalidomide (Revlimid) as a consolidation strategy in patients with chronic lymphocytic leukemia (CLL) who have residual disease after treatment. This study reported good response improvements (in 45% of patients with residual disease). Lenalidomide may be particularly suited as a consolidation strategy after...
Read MoreIn a nutshell This trial looked at factors which would help predict whether aggressive radiation would be beneficial to patients with extensive stage small cell lung cancer who have progressed passed chemotherapy. The authors concluded that patients with less than three metastases (spread of cancer) would benefit most. Some background...
Read More
In a nutshell This study looked survival rates of stage II rectal cancer patients who underwent different treatments. It compared radical surgery versus local excision with added-on chemoradiation. The article concluded that overall survival was not different between the treatments. Some background Radical surgery (RS – complete...
Read More
In a nutshell This study reviewed the use of CAR-T cell therapy, a new type of immunotherapy, for acute myeloid leukemia (ALL). Some background Chemotherapy is often the first-line treatment for AML. In cases of a relapse (return of the disease), alternative treatment options are usually explored. This is because many patients develop a resistance...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of poziotinib in treating locally advanced (spread to nearby tissue) or metastatic (spread to other parts of the body) non-small cell lung cancer (NSCLC) with an EGFR mutation. The primary outcome will be measured by the response rate to the treatment. This trial is being conducted...
Read More
